Sure. Our current projected growth rate for this fiscal year is about 8.3% in our pharmaceutical benefit, and that's up from previous years where we were quite a bit lower than that.
In our plan, one of the main drivers of growth is always new clients accessing the benefits. Population growth among first nations and Inuit is nearly double the Canadian growth rate, so we have a strong underlying population effect.
What we're dealing with right now in terms of drug coverage is that we have strong growth in our hepatitis C medication coverage. We're up about 30% on that. Opioid addiction therapies—drugs like buprenorphine, under the brand name of Suboxone, or methadone—are up significantly, as are biologic medications—drugs for rheumatoid arthritis, Crohn's disease—as Sony mentioned in his opening remarks.
With oral chemotherapy, it was noted that we're seeing a shift from hospital-based chemotherapy coverage to drugs that are now in tablet format and they're coming into our reimbursement environment, so we're seeing a significant growth in terms of our payment of oral chemotherapy. For infectious diseases such as HIV/AIDS medication as well, as more clients are diagnosed they're put on drug regimes that can cost $10,000 to $15,000 annually.
Those are the types of examples in which we're seeing growth pressure.